Locations:
Search IconSearch
December 2, 2018/Cancer/Research

The Next Step in Immunotherapy for Myeloid Hematologic Malignancies

Study explores atezolizumab for myelodysplastic syndrome

chemo-drug_650x450

Aside from lenalidomide for a small subset of patients, there’s really only one class of FDA-approved medications for patients with myelodysplastic syndrome (MDS), hypomethylating agents (HMA).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“That’s not a lot for a disease that affects between 60,000 and 170,000 people in the U.S.,” says Aaron Gerds, MD, MS, of Cleveland Clinic Cancer Center.

While HMAs — namely azacitidine and decitabine — are effective for many, there are limited treatment options (outside of bone marrow transplant) for MDS patients who don’t respond to them. That, combined with research showing higher PD-L1 expression in MDS patients who fail HMA therapy, has triggered multiple studies on the role of immunotherapy in MDS.

Three of them, including a study by Dr. Gerds, were presented in tandem at the 2018 American Society of Hematology meeting in San Diego.

“It’s tough to interpret these studies because they’re only phase 1 and 2, and survival outcomes take years to track,” says Dr. Gerds. “But immunotherapy has been so successful in lymphoma, lung and other cancers that it makes sense we start exploring it for myeloid hematologic malignancies too.”

Can atezolizumab improve outcomes in MDS?

Dr. Gerds and a multicenter team researched the safety and tolerability of anti-PD-L1 monoclonal antibody atezolizumab, both with and without HMA azacitidine, in MDS patients who had either failed or never received conventional HMA therapy.

More than 40 MDS patients (median age 76) made up three cohorts:

  1. High-risk MDS patients who had failed HMA treatment. These 10 patients received 1,200 mg of atezolizumab every three weeks.
  2. Additional high-risk MDS patients who had failed HMA treatment. These 11 patients received six cycles of 840 mg of atezolizumab every two weeks and 75 mg/m2 of azacitidine for seven days every four weeks, followed by a maintenance dose of 1,200 mg of atezolizumab every three weeks.
  3. High-risk MDS patients who had never received HMA treatment. These 21 patients received 840 mg of atezolizumab every two weeks and 75 mg/m2 of azacitidine for seven days every four weeks.

Advertisement

Overall response was 0 percent for Cohort A (with median overall survival of 5.9 months), 9 percent for Cohort B (with median overall survival of 10.7 months) and 62 percent for Cohort C (with median overall survival undetermined as eight patients remain on therapy).

However, the study was terminated early because of adverse events, including death.

More than 30 percent of patients receiving the combined therapy (Cohorts B and C) had grade 3-5 febrile neutropenia (compared to 10 percent of those receiving the monotherapy, Cohort A).

Serious adverse events caused all six deaths (29 percent of patients) in previously untreated patients (Cohort C). Deaths in cohorts A (70 percent of patients) and B (64 percent of patients) were more commonly due to disease progression. Nearly 30 percent of deaths in Cohort C occurred within 90 days of the study treatment, compared to a median of 160 days in Cohort A and 299 days in Cohort B.

A word of caution: Beware unexpected toxicities

“We had expected Cohort C — the patients who hadn’t had prior treatment — to be the healthiest and fittest, not the one with the most unfavorable safety profile,” says Dr. Gerds. “Our study reinforces that patients with MDS can be frail, and new combinations of drugs can cause unexpected toxicities. It’s a word of caution to the medical community.”

Moving the field forward and finding better treatments for patients is a must, he notes. But physician researchers should proceed cautiously and methodically. More needs to be understood about the toxicity differences between MDS patients who have failed HMA treatment and those that never received it. That will inform future studies combining HMA and immunotherapy.

Advertisement

“Immunotherapies have done a lot of good for many cancer patients. That’s why studies like ours need to be done,” says Dr. Gerds. “But we should start by dipping a toe in the water, not jumping in with both feet. First, do no harm.”

Advertisement

Related Articles

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Hereditary Hemorrhagic Telangiectasia
September 23, 2024/Cancer/Research
Pomalidomide Effective in Treating Hereditary Hemorrhagic Telangiectasia

Oral medication reduces epistaxis and improves quality of life for patients with rare vascular disorder

Radiation therapy
September 17, 2024/Cancer/Research
ASTRO 2024 Highlights

A preview for radiation oncologists

Dr. Shilpa Gupta
September 16, 2024/Cancer/Research
New Studies Reinforce Benefits of Combination Treatment for Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression

Before and after scan
August 28, 2024/Cancer/Research
Case Study: Patient with Metastatic Urothelial Carcinoma Has No Remaining Evidence of Disease

Treatment involved checkpoint inhibitor, surgery and intravesical therapy

Dr. Maciejewski
August 23, 2024/Cancer/Research
Studies Evaluate Anti-Complement Inhibitors for Treating Paroxysmal Nocturnal Hemoglobinuria

Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials

Dr. Raza
August 19, 2024/Cancer/Research
Understanding the Role of Palliative Care in AL Amyloidosis

Multi-specialty coordination essential for improving quality of life

Ad